Contact
searchSearch
HMP Global
Login

Leukemia & Lymphoma Excellence Forum

Leukemia & Lymphoma Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Sarah Rutherford, MD
Videos
Approaches and Strategies for Treating Elderly Patients With Hodgkin Lymphoma
10/17/2025
Sarah C. Rutherford, MD
At the 2025 Lymphoma, Leukemia, & Myeloma Congress, Sarah Rutherford, MD, shares case presentations of elderly patients with Hodgkin lymphoma and the strategies she utilizes to treat these patients.
At the 2025 Lymphoma, Leukemia, & Myeloma Congress, Sarah Rutherford, MD, shares case presentations of elderly patients with Hodgkin lymphoma and the strategies she utilizes to treat these patients.
At the 2025 Lymphoma, Leukemia,...
10/17/2025
Oncology
Ibrahim Aldoss, MD
Conference Coverage
Ponatinib vs Imatinib for Patients Without MRD Negativity at End of Induction: Phase 3 PhALLCON Trial
06/01/2025
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD shares results from a post hoc analysis of the phase 3 PhALLCON study which showed clinical benefit with ponatinib vs imatinib for patients with ALL who did not achieve MRD negativity by end of induction.
Ibrahim Aldoss, MD shares results from a post hoc analysis of the phase 3 PhALLCON study which showed clinical benefit with ponatinib vs imatinib for patients with ALL who did not achieve MRD negativity by end of induction.
Ibrahim Aldoss, MD shares...
06/01/2025
Oncology
Craig Moskowitz, MD
Conference Coverage
Updates in Standard of Care and Disease Management Strategies for Patients With Hodgkin Lymphoma
03/05/2025
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses...
03/05/2025
Oncology
Peter Martin, MD
Conference Coverage
Novel Advancements in Marginal Zone Lymphoma Research
10/29/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia &...
10/29/2024
Oncology
Mrinal Patnaik, MD
Conference Coverage
Exploring Diagnostic Criteria and Treatment Options for Patients With CMML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology
Myron Czuczman, MD
Videos
Insights into the FDA Approval of Denileukin Diftitox for R/R Cutaneous T-Cell Lymphoma Treatment
08/27/2024
Myron Czuczman, MD, discusses Pivotal Study 302, which led to the FDA approval of denileukin diftitox for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma.
Myron Czuczman, MD, discusses Pivotal Study 302, which led to the FDA approval of denileukin diftitox for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma.
Myron Czuczman, MD, discusses...
08/27/2024
Oncology
Jakub Svoboda, MD
Conference Coverage
Examining Efficacy and Safety of Novel Armored huCART19-IL18 Treatment for Patients With R/R Lymphoma
06/13/2024

Featuring Jakub Svoboda, MD

Featuring Jakub Svoboda, MD ...
Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.
Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.
Jakub Svoboda, MD, discusses...
06/13/2024
Oncology
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma
04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA,...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Julie Vose, MD
Videos
Advances in Treatment Options for Patients With T-Cell Lymphoma
10/24/2023
Julie Vose, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia &...
10/24/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Predicting Long-Term Effects Among Patients Treated for Early-Stage Hodgkin Lymphoma
09/07/2023
Andrew M. Evens, DO, MSc
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates &...
09/07/2023
Oncology

What Your Colleagues Are Reading

Expert Roundtable
Videos
Strategies for Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
11/15/2024
In part 3 of this expert roundtable series, Jorge Cortes, MD, provides insight into strategies for treating patients with relapsed/refractory acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 3 of this expert roundtable series, Jorge Cortes, MD, provides insight into strategies for treating patients with relapsed/refractory acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 3 of this expert...
11/15/2024
Oncology
News
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Stephanie Holland
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology
Quiz
At what baseline spleen size do you typically consider initiating treatment for a patient with MF who presents with mild to moderate symptoms?
12/13/2024
12/13/2024
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Stephanie Holland
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Potential New Standard of Care for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer
01/27/2025
Allison Casey
According to results from the phase 3, CheckMate 8HW trial, nivolumab plus ipilimumab demonstrated superior PFS compared with nivolumab monotherapy for patients with microsatellite instability-high, mismatch repair-deficient metastatic...
According to results from the phase 3, CheckMate 8HW trial, nivolumab plus ipilimumab demonstrated superior PFS compared with nivolumab monotherapy for patients with microsatellite instability-high, mismatch repair-deficient metastatic...
According to results from the...
01/27/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use